Hülya Güngel, Ozen Osmanbasoglu, Ebru Demet Aygit (Istanbul, Turkey)


To evaluate the clinical findings and treatment outcomes in patients with central retinal vein obstruction (CRVO).


16 patients’ data that were followed more than 6 months were evaluated. Based on the angiographic findings patients were grouped as ischemic and non-ischemic CRVO. Visual acuity, OCT findings and treatment modalities were analyzed.

Effectiveness / Safety:

8 patients had non ischemic CRVO, 2 received 1 intravitreal triamcinolone acetonid injection (IVTA), 2 had 1 IVTA combined with bevacizumab injection, 1 underwent pars plana vitrectomy for vitreomacular traction and 1 patient received bevacizumab after 4 IVTA injections for intractable cystoid macular edema (CME) over a 2 year period. 2 patients with visual acuities 0,7 and 0,8 SR respectively was followed without treatment. 8 patients had ischemic CRVO, 3 had IVTA combined with bevacizumab injection, one had 1 bevacizumab injection, the other one had 1 IVTA injection, 5 patients (1 with disc neovascularization, 1 with rubeosis iridis at presentation) had pan retinal laser photocoagulation, 1 patient underwent epiretinal membrane (ERM) removal. Visual acuity improved in 4 patients and remained stable in the other 4 in non-ischemic group while remained stable in 5, improved in 2 and decreased in 1 patient in ischemic group. Regarding the last OCT findings, 6 patients had less than 300 µm and 2 had over 450 µm (1 ERM, 1 intractable CME) central foveal thickness in non-ischemic group. Central foveal thickness persisted over 350 µm despite treatment in 6 patients in ischemic group.

Take home message:

Intravitreal triamcinolone injection has favorable effect on visual acuity and OCT findings in non-ischemic CRVO. IVTA combined with bevacizumab was not found effective regarding visual acuity and OCT findings in ischemic CRVO.